TGTX - TG Therapeutics Inc
IEX Last Trade
23.47
-0.040 -0.170%
Share volume: 2,936,370
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$23.51
-0.04
-0.17%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-09 | 2022-11-09 | 2023-03-01 | 2023-05-08 | 2023-08-04 | 2023-11-06 | 2024-02-29 | 2024-05-06 | |
| Assets | |||||||||
| Total Assets | 251.666 M | 217.891 M | 193.572 M | 197.358 M | 220.854 M | 331.067 M | 329.587 M | 373.323 M | |
| Current Assets | 202.560 M | 182.922 M | 168.274 M | 184.783 M | 208.574 M | 319.114 M | 317.943 M | 360.581 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 27.221 M | 30.234 M | 33.553 M | 39.823 M | 77.719 M | |
| Other Current Assets | 6.763 M | 6.980 M | 6.596 M | 9.229 M | 15.951 M | 17.082 M | 9.519 M | 8.095 M | |
| Short Term Investments | 6.763 M | 6.980 M | 6.596 M | 9.229 M | 15.951 M | 17.082 M | 9.519 M | 8.095 M | |
| Total Receivables | 88.000 K | 0.000 | 0.000 | 8.623 M | 17.484 M | 39.320 M | 51.093 M | 64.982 M | |
| Current Cash | 195.709 M | 175.942 M | 161.678 M | 139.710 M | 144.905 M | 229.159 M | 217.508 M | 209.785 M | |
| Total Non-current Assets | 49.106 M | 34.969 M | 25.298 M | 12.575 M | 12.280 M | 11.953 M | 11.644 M | 12.742 M | |
| Property Plant Equipment | 2.180 M | 2.056 M | 1.934 M | 1.811 M | 1.727 M | 1.601 M | 1.510 M | 1.428 M | |
| Other Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 799.000 K | 799.000 K | 799.000 K | 799.000 K | 799.000 K | 799.000 K | 799.000 K | 799.000 K | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 251.666 M | 217.891 M | 193.572 M | 197.358 M | 220.854 M | 331.067 M | 329.587 M | 373.323 M | |
| Total liabilities | 122.631 M | 117.410 M | 134.985 M | 169.925 M | 180.401 M | 166.298 M | 169.085 M | 213.214 M | |
| Total current liabilities | 43.326 M | 36.447 M | 53.201 M | 63.076 M | 72.667 M | 57.678 M | 53.720 M | 99.684 M | |
| Accounts Payable | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 381.000 K | 343.000 K | 305.000 K | 267.000 K | 229.000 K | 190.000 K | 6.016 M | 3.244 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 68.947 M | 70.038 M | 71.135 M | 96.503 M | 97.700 M | 98.908 M | 100.118 M | 101.326 M | |
| Other liabilities | 381.000 K | 343.000 K | 305.000 K | 267.000 K | 229.000 K | 190.000 K | 6.016 M | 3.244 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 129.035 M | 100.481 M | 58.587 M | 27.433 M | 40.453 M | 164.769 M | 160.502 M | 160.109 M | |
| Common stock | 134.780 M | 135.327 M | 137.138 M | 140.312 M | 141.504 M | 142.871 M | 143.133 M | 146.209 M | |
| Retained earnings | -1.438 B | -1.474 B | -1.527 B | -1.566 B | -1.614 B | -1.500 B | -1.514 B | -1.525 B |